Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.

Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.

INTRODUCTION: We report the efficacy and safety of crizotinib treatment among Chinese patients with advanced-stage NSCLC. METHODS: We retrospectively analyzed patients with EML4-ALK positive advanced NSCLC who were treated with crizotinib from May 2012 to Aug 2013. Baseline clinical parameters, trea...

Full description

Bibliographic Details
Main Authors:	Yabing Cao, Guangli Xiao, Xibin Qiu, Sheng Ye, Tongyu Lin
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4264693?pdf=render

Similar Items

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
by: Yen-Ting Lin, et al.
Published: (2019-09-01)

Efficacy and Safety of Crizotinib in Advanced or Recurrent  ALK-positive Non-small Cell Lung Cancer
by: Xiaoyan LI, et al.
Published: (2019-08-01)

lincROR influences the stemness and crizotinib resistance in EML–ALK+ non-small-cell lung cancer cells
by: Yang Y, et al.
Published: (2018-06-01)

A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib
by: Jon H. Chung, et al.
Published: (2014-09-01)

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
by: Katayama, Ryohei, et al.
Published: (2011)

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
by: Jing ZHAO, et al.
Published: (2015-10-01)

Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report
by: Ling Zhang, et al.
Published: (2018-06-01)

Bilateral breast adenocarcinomas with EML4—ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site?
by: Liu C, et al.
Published: (2016-06-01)

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion
by: Aguado C, et al.
Published: (2018-03-01)

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
by: Daijiro Harada, et al.
Published: (2021-03-01)

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib
by: Liang H, et al.
Published: (2019-09-01)

EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER
by: A. A. Paichadze, et al.
Published: (2020-03-01)

EML4-ALK Fusion Gene in Lung Cancer and Its Biological Function
by: Tong YANG, et al.
Published: (2012-02-01)

EML4-ALK Fusion Lung Cancer: A Rare Acquired Event
by: Sven Perner, et al.
Published: (2008-03-01)

ALK positive histiocytosis in an adult female with an EML4-ALK RNA fusion
by: Jay Mehta, et al.
Published: (2020-09-01)

Genes of ancient microtubule-stabilizing proteins traveled through pre-Cambrian Echinoidea to advanced life forms of dry land and ended up in the human genome as the fusion oncogenes-oncoproteins eml1/EML1-abl/ABL, and eml4/EML4-alk/ALK
by: J G Sinkovics
Published: (2016-03-01)

Genes of ancient microtubule-stabilizing proteins traveled through pre-Cambrian Echinoidea to advanced life forms of dry land and ended up in the human genome as the fusion oncogenes-oncoproteins eml1/EML1-abl/ABL, and eml4/EML4-alk/ALK
by: JG Sinkovics
Published: (2016-03-01)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
by: Cao Q, et al.
Published: (2019-02-01)

Fusion of <it>EML4 </it>and <it>ALK </it>is associated with development of lung adenocarcinomas lacking <it>EGFR </it>and <it>KRAS </it>mutations and is correlated with ALK expression
by: Zhang Xuchao, et al.
Published: (2010-07-01)

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
by: Athanasios R Paliouras, et al.
Published: (2020-07-01)

Mechanisms of Resistance to EML4-ALK Inhibitors in Non-small Cell Lung Cancer
by: Di WU, et al.
Published: (2013-01-01)

Erratum: EML4-ALK Fusion Gene in Lung Cancer and Its Biological Function
by: Editorial Office of Chinese Journal of Lung Cancer
Published: (2012-11-01)

Phase separation of EML4–ALK in firing downstream signaling and promoting lung tumorigenesis
by: Zhen Qin, et al.
Published: (2021-05-01)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
by: Rui-Lian Chen, et al.
Published: (2018-11-01)

Use of crizotinib for refractory ALK-positive lymphomas
by: L N Shelikhova, et al.
Published: (2017-07-01)

ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells
by: Anna M. Schläfli, et al.
Published: (2021-04-01)

Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer
by: Mohieldin A, et al.
Published: (2018-11-01)

The EML4-ALK Fusion Gene in NSCLC and the Clinical Progress
by: Hong YU, et al.
Published: (2011-05-01)

ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
by: Christabel Wilson, et al.
Published: (2017-10-01)

Fatal Haemoptysis Associated with Dramatic Response to Crizotinib in an ALK-Rearranged Lung Adenocarcinoma
by: Elodie Mussat, et al.
Published: (2016-03-01)

The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma
by: Didik S. Heriyanto, et al.
Published: (2020-01-01)

A case of lung adenocarcinoma harboring <it>EGFR</it> mutation and <it>EML4-ALK</it> fusion gene
by: Tanaka Hisashi, et al.
Published: (2012-11-01)

A Case Report: an EML4-ALK Positive Lung Adenocarcinoma Diagnosed  with Lymphoma Previously
by: Li LIU, et al.
Published: (2015-02-01)

Clinical Meaning of EML4-ALK Fusion Gene in Non-small Cell Lung Cancer
by: Wei HAN, et al.
Published: (2013-02-01)

Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung
by: Shafik Hanan Ezzat, et al.
Published: (2015-06-01)

Clinicopathologic Features of Non-Small Cell Lung Cancer with EML4-ALK Fusion Gene.
by: Takahashi, Tsuyoshi
Published: (2010)

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients
by: Jacques Cadranel, et al.
Published: (2018-02-01)

Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study.
by: Yabing Cao, et al.
Published: (2019-01-01)

Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report
by: Xueqian Wu, et al.
Published: (2020-06-01)

ALK-driven tumors and targeted therapy: focus on crizotinib
by: Murga-Zamalloa C, et al.
Published: (2014-03-01)